کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8791992 | 1602552 | 2018 | 34 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells
ترجمه فارسی عنوان
اثر بریمونیدین، آگونیست آری آ -2 آدرنرژیک بر روی سلول های اپیتلیال غدد میبومی انسان
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ERKDEDMGDLC3ABPEp38SREBP-1FBSJnkIBMXKSFMEGFα2 adrenergic agonist3-isobutyl-1-methylxanthine - 3-ایزوبوتیل-1-متیلکسانتینc-Jun N-terminal kinases - C-Jun N-terminal kinasescAMP - cAMPDMEM/F12 - DMEM / F12Akt - آکتmeibomian gland dysfunction - اختلال عملکرد غدد meibomiabrimonidine - بریمونیدینDry eye disease - بیماری چشم خشکcationic amphiphilic drug - داروی amphiphilic کاتیونیfetal bovine serum - سرم جنین گاوCAD - طراحی به کمک رایانه یا کَدepidermal growth factor - عامل رشد اپیدرمیbovine pituitary extract - عصاره هیپوفیز گاوphospholipidosis - فسفولیپیدوزLAMP-1 - لامپ 1sterol regulatory element-binding protein 1 - پروتئین اتصال دهنده عصاره استرول 1Lysosomal-associated membrane protein 1 - پروتئین غشای مرتبط با لیزوزوم 1p38 mitogen activated protein kinase - پروتئین کیناز فعال میتوکندر P38keratinocyte serum-free medium - کراتینوسیت بدون سرمextracellular signal-regulated kinase - کیناز تنظیم شده سیگنال خارج سلولی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی و میکروب شناسی (عمومی)
چکیده انگلیسی
We recently discovered that the anti-glaucoma pharmaceuticals timolol, a β adrenergic antagonist, and pilocarpine, a cholinergic compound, negatively influence the morphology, proliferative capacity and survival of human meibomian gland epithelial cells (HMGECs). We hypothesize that another class of anti-glaucoma drugs, the α2 adrenergic agonists, also acts directly on HMGECs to affect their structure and function. We tested this hypothesis. Immortalized (i) HMGECs were cultured with brimonidine, as well as clonidine (α2 agonist), phenylephrine (α1 agonist), RX821002 (inverse α2 agonist) and MK912 (neutral α2 agonist) for up to 7 days. Cells were counted with a hemocytometer, and evaluated for morphology, signaling pathway activity, protein biomarker expression, and the accumulation of neutral lipids, phospholipids and lysosomes. Our findings demonstrate that brimondine treatment induces a dose-dependent decrease in Akt signaling and proliferation of iHMGECs. In contrast, brimonidine also promotes a dose-dependent differentiation of iHMGECs, including an increase in neutral lipid, phospholipid and lysosome levels. These effects were paralleled by an inhibition of p38 signaling, and duplicated by cellular exposure to clonidine, but not phenylephrine. Brimonidine also enhanced the cellular content of sterol regulatory binding protein-1, a master regulator of lipid synthesis. Of particular interest, the putative α2 antagonists, RX821002 and MK912, did not interfere with brimonidine action, but rather stimulated IHMGEC differentiation. Our results support our hypothesis and demonstrate that α2 adrenergic agonists act directly on iHMGECs. However, these compounds do not elicit an overall negative effect. Rather, the α2 agonists promote the differentiation of iHMGECs.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Experimental Eye Research - Volume 170, May 2018, Pages 20-28
Journal: Experimental Eye Research - Volume 170, May 2018, Pages 20-28
نویسندگان
Xi Han, Yang Liu, Wendy R. Kam, David A. Sullivan,